Dyadic International Yönetim

Yönetim kriter kontrolleri 3/4

Dyadic International CEO'su Mark Emalfarb, Oct2004 tarihinde atandı, in görev süresi 20.08 yıldır. in toplam yıllık tazminatı $ 1.04M olup, şirket hissesi ve opsiyonları dahil olmak üzere 54.5% maaş ve 45.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 27.73% ine doğrudan sahiptir ve bu hisseler $ 15.84M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.3 yıl ve 10 yıldır.

Anahtar bilgiler

Mark Emalfarb

İcra Kurulu Başkanı

US$1.0m

Toplam tazminat

CEO maaş yüzdesi	54.5%
CEO görev süresi	20.1yrs
CEO sahipliği	27.7%
Yönetim ortalama görev süresi	3.3yrs
Yönetim Kurulu ortalama görev süresi	10yrs

Son yönetim güncellemeleri

Recent updates

Does Dyadic International (NASDAQ:DYAI) Have A Healthy Balance Sheet?

Jul 17

Is Dyadic International (NASDAQ:DYAI) In A Good Position To Deliver On Growth Plans?

Mar 14

Is Dyadic International (NASDAQ:DYAI) In A Good Position To Invest In Growth?

Oct 28

Here's Why We're Watching Dyadic International's (NASDAQ:DYAI) Cash Burn Situation

Jun 21

We're Hopeful That Dyadic International (NASDAQ:DYAI) Will Use Its Cash Wisely

Oct 05

Dyadic collaborates with Syngene International to develop a COVID-19 vaccine candidate

May 26

We're Not Very Worried About Dyadic International's (NASDAQ:DYAI) Cash Burn Rate

May 03

Dyadic International's (NASDAQ:DYAI) Wonderful 318% Share Price Increase Shows How Capitalism Can Build Wealth

Feb 22

Dyadic International (NASDAQ:DYAI) Is In A Good Position To Deliver On Growth Plans

Jan 18

Do Insiders Own Lots Of Shares In Dyadic International, Inc. (NASDAQ:DYAI)?

Dec 10

Dyadic International reports Q3 results

Nov 12

CEO Tazminat Analizi

Mark Emalfarb'un ücretlendirmesi Dyadic International'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$6m
Jun 30 2024	n/a	n/a	-US$8m
Mar 31 2024	n/a	n/a	-US$8m
Dec 31 2023	US$1m	US$569k	-US$7m
Sep 30 2023	n/a	n/a	-US$7m
Jun 30 2023	n/a	n/a	-US$7m
Mar 31 2023	n/a	n/a	-US$8m
Dec 31 2022	US$1m	US$546k	-US$10m
Sep 30 2022	n/a	n/a	-US$12m
Jun 30 2022	n/a	n/a	-US$12m
Mar 31 2022	n/a	n/a	-US$12m
Dec 31 2021	US$1m	US$525k	-US$13m
Sep 30 2021	n/a	n/a	-US$11m
Jun 30 2021	n/a	n/a	-US$12m
Mar 31 2021	n/a	n/a	-US$10m
Dec 31 2020	US$1m	US$500k	-US$9m
Sep 30 2020	n/a	n/a	-US$9m
Jun 30 2020	n/a	n/a	-US$8m
Mar 31 2020	n/a	n/a	-US$8m
Dec 31 2019	US$1m	US$440k	-US$8m
Sep 30 2019	n/a	n/a	-US$7m
Jun 30 2019	n/a	n/a	-US$7m
Mar 31 2019	n/a	n/a	-US$6m
Dec 31 2018	US$1m	US$393k	-US$6m
Sep 30 2018	n/a	n/a	-US$7m
Jun 30 2018	n/a	n/a	-US$7m
Mar 31 2018	n/a	n/a	-US$6m
Dec 31 2017	US$1m	US$382k	-US$2m

Tazminat ve Piyasa: Mark 'nin toplam tazminatı ($USD 1.04M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 647.72K ).

Tazminat ve Kazançlar: Mark 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Mark Emalfarb (68 yo)

20.1yrs

Görev süresi

US$1,044,244

Tazminat

Mr. Mark A. Emalfarb Founded Dyadic International Inc., in 1979 and has been its Chief Executive Officer since October 2004. Mr. Emalfarb has been the President of Dyadic International Inc., since October...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mark Emalfarb	Founder	20.1yrs	US$1.04m	27.73% $ 15.8m
Ping Rawson	Chief Financial Officer	5.4yrs	US$412.13k	0.41% $ 232.0k
Joseph Hazelton	Chief Operating Officer	less than a year	US$437.75k	0.34% $ 191.4k
Doug Pace	Executive Vice President of Business Development	1.1yrs	Veri yok	Veri yok
Ana Rodriguez	Secretary of the Board	no data	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

50yo

Ortalama Yaş

Deneyimli Yönetim: DYAI 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mark Emalfarb	Founder	16.4yrs	US$1.04m	27.73% $ 15.8m
Arkady Sinitsyn	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Cees van den Hondel	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Arnold Demain	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Jack Kaye	Independent Director	9.5yrs	US$124.81k	0.11% $ 64.8k
Michael Tarnok	Independent Director	10.4yrs	US$124.81k	0.75% $ 427.8k
Seth Herbst	Independent Director	16.4yrs	US$95.71k	0.45% $ 255.1k
Patrick Lucy	Independent Chairman	3.8yrs	US$95.71k	0.092% $ 52.4k
Arindam Bose	Independent Director	8.3yrs	US$124.81k	0.092% $ 52.4k

10.0yrs

Ortalama Görev Süresi

67.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: DYAI 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 10 yıldır).

Dyadic International Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Founder notifies of intention to sell stock

Dyadic International, Inc., Annual General Meeting, Jun 11, 2024

Dyadic International, Inc. Announces Management Changes

Insufficient new directors

Insufficient new directors

Dyadic International, Inc. Announces Executive Changes

Recent updates

New minor risk - Share price stability

Consensus revenue estimates increase by 48%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Dyadic International, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Consensus revenue estimates decrease by 22%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Dyadic International, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Does Dyadic International (NASDAQ:DYAI) Have A Healthy Balance Sheet?

Price target decreased by 12% to US$7.50

Founder notifies of intention to sell stock

New minor risk - Share price stability

Consensus revenue estimates decrease by 17%

First quarter 2024 earnings released: US$0.07 loss per share (vs US$0.033 loss in 1Q 2023)

Dyadic International, Inc. to Report Q1, 2024 Results on May 14, 2024

Dyadic International, Inc., Annual General Meeting, Jun 11, 2024

Consensus EPS estimates fall by 159%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Dyadic International, Inc. Announces Management Changes

Dyadic International, Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Dyadic International, Inc. Announces Top-Line Results from Its Successful Phase 1 Clinical Trial for A First-In-Human Filamentous Fungal-Based Vaccine Candidate

New minor risk - Profitability

Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Consensus revenue estimates increase by 25%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Dyadic International, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Dyadic International, Inc Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate

Consensus revenue estimates increase by 74%

First quarter 2023 earnings released: US$0.033 loss per share (vs US$0.088 loss in 1Q 2022)

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Is Dyadic International (NASDAQ:DYAI) In A Good Position To Deliver On Growth Plans?

Dyadic International, Inc. Initiates Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

An unknown buyer acquired 1.99% stake in Alphazyme LLC from Dyadic International, Inc. (NasdaqCM:DYAI) for $1.27 million.

Consensus forecasts updated

Insufficient new directors

Consensus revenue estimates fall by 53%

Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for Dyai-100 Covid-19 Recombinant Protein Rbd Booster Vaccine Candidate

Is Dyadic International (NASDAQ:DYAI) In A Good Position To Invest In Growth?

Consensus revenue estimates fall by 31%

Forecast to breakeven in 2023

Dyadic International, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Here's Why We're Watching Dyadic International's (NASDAQ:DYAI) Cash Burn Situation

Consensus forecasts updated

Price target decreased to US$7.50

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Dyadic International, Inc. Announces Successful Toxicology Data Published in Toxicologic Pathology

Insufficient new directors

Dyadic International, Inc. Announces Executive Changes

Consensus revenue estimates fall by 42%

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Dyadic International, Inc. Introduces Novel Method to Produce Synthetic Cannabinoids and Precursors Utilizing C1 Cell Line Production Platform and Patent Pending Process

Dyadic International, Inc. Announces A National Institute for Innovation in Manufacturing Biopharmaceuticals Coronavirus Grant Under the White House’s American Rescue Plan

Forecast to breakeven in 2023

Price target decreased to US$8.50

Third quarter 2021 earnings released: US$0.061 loss per share (vs US$0.091 loss in 3Q 2020)

We're Hopeful That Dyadic International (NASDAQ:DYAI) Will Use Its Cash Wisely

Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.097 loss in 2Q 2020)

Dyadic International, Inc.(NasdaqCM:DYAI) dropped from Russell 3000E Value Index

Chief Financial Officer recently bought US$59k worth of stock

Dyadic collaborates with Syngene International to develop a COVID-19 vaccine candidate

First quarter 2021 earnings released: US$0.12 loss per share (vs US$0.081 loss in 1Q 2020)

We're Not Very Worried About Dyadic International's (NASDAQ:DYAI) Cash Burn Rate

Consensus forecasts updated

Full year 2020 earnings released: US$0.34 loss per share (vs US$0.31 loss in FY 2019)

Dyadic Advancing Towards Human Clinical Trial of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100

Dyadic International's (NASDAQ:DYAI) Wonderful 318% Share Price Increase Shows How Capitalism Can Build Wealth

New 90-day high: US$6.79

Independent Director exercised options to buy US$290k worth of stock.

Dyadic International, Inc. Enters Collaboration with Turtle Tree Scientific